Hot Topics: Impact of Biomarkers Market Overview in Alzheimer%s Disease - Dx-Rx collaboration paves the way for personalized medicine

• Publication date: December 2011

About This Report Diagnostic and prognostic biomarkers will help to identify patients with early Alzheimer’s disease, while pharmacogenetic biomarkers can inform prescribing decisions and form the basis of personalized medicine. Biomarkers are at the heart of the development of two high-risk pipeline drugs, bapineuzumab and solanezumab, with combined peak-year revenue projections of USD 6.6bn in the seven major industries. ...

About This Report

Diagnostic and prognostic biomarkers will help to identify patients with early Alzheimer’s disease, while pharmacogenetic biomarkers can inform prescribing decisions and form the basis of personalized medicine. Biomarkers are at the heart of the development of two high-risk pipeline drugs, bapineuzumab and solanezumab, with combined peak-year revenue projections of USD 6.6bn in the seven major industries.

What's Included in This Report?


* Identify the imaging, fluid, and genetic biomarkers currently under clinical evaluation.

* Understand the potential roles of biomarker tests in the diagnosis and treatment of Alzheimer’s disease.

* Review the tools used to diagnose Alzheimer’s disease by neurologists surveyed by Datamonitor in 2011.

* Quantify the impact that biomarkers may have on the Alzheimer’s disease drug industry from 2011 to 2020.

* View insights from Datamonitor’s interviews with internationally renowned key opinion leaders.

Key Market Facts

The Alzheimer’s disease industry is projection to grow to 2020 at a CAGR of 10.7% from 2011. Catalysts for growth include an aging population, earlier diagnosis, and the introduction of immunotherapies. The absolute impact of biomarkers is predicted to be USD 6.6bn annually by 2020 with the potential for far greater implications beyond this period.
The last 2 years have seen a spate of collaborations between drug and diagnostic firms . This has allowed drug developers to be at the forefront of diagnostic research; enabling optimized patient recruitment and generating important biomarker data. Furthermore, the potential for allying a new drug to a companion diagnostic is created.
Diagnostic biomarkers to identify MCI due to Alzheimer’s may increase the likelihood that a drug with an anti-amyloid mechanism will show efficacy. Furthermore, pharmacogenetic biomarkers, such as ApoE4 status with bapineuzumab, can identify patients that will be more likely to respond to a treatment with an acceptable safety profile.

Why Should You Buy This Report?


* How will biomarker tests alter the diagnostic and therapeutic landscape for Alzheimer’s disease?

* Why is early diagnosis so important in Alzheimer’s disease and how will biomarker tests facilitate this?

* What will the absolute impact of biomarkers be on the Alzheimer’s disease drug industry to 2020?

* How will key stakeholders stand to benefit from the advent of personalized medicine?

Genomics Industry

Summary
Strategic scoping and focus
Datamonitor key findings
Related reports
OVERVIEW
Catalyst
Summary
INTRODUCTION
Alzheimer’s disease diagnosis
NINCDS-ADRDA criteria
NIA-AA criteria
ALZHEIMER’S DISEASE BIOMARKERS
Biomarkers under investigation
Structural imaging: MRI
Functional imaging: PET and SPECT
Fluid biomarker analysis
Genetic biomarkers
Potential roles of Alzheimer’s disease biomarkers
Diagnostic and prognostic
Treatment response
IMPACT OF BIOMARKERS ON THE ALZHEIMER’S DISEASE DRUG MARKET
Industry dynamics
Biomarkers provide the potential platform for double-digit growth in the Alzheimer’s disease industry
Bapineuzumab and solanezumab, two of the potential high-value Alzheimer’s immunotherapies, rely heavily on biomarkers
Indication dynamics
High value lies in the early treatment of Alzheimer’s disease
DIAGNOSTIC STAKEHOLDERS
Diagnostic firms
Spate of collaborations between diagnostic industry players and drug developers
There are multiple advantages to a personalized medicine approach to Alzheimer’s disease
Imaging manufacturers
PET scans will become increasingly common in Alzheimer’s disease diagnosis
BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
APPENDIX A
Physician research methodology
Physician sample breakdown
The survey questionnaire
Diagnosis techniques currently in use for Alzheimer’s disease
APPENDIX B
PharmaVitae Explorer database
Contributing experts
Conferences attended
Projection methodology
Industry definition for this disease
Projection methodology and hypothesis s
Report methodology